Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches
Melisa Tecik, Aysun Adan
OncoTargets and Therapy (2022) Vol. Volume 15, pp. 1449-1478
Open Access | Times Cited: 19

Showing 19 citing articles:

A Review of FLT3 Kinase Inhibitors in AML
Cristina Negotei, Andrei Coliță, Iuliana Mitu, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 20, pp. 6429-6429
Open Access | Times Cited: 20
Light-Controlled Peptide Ligands for the Photoaffinity Purification of FLT3 and CD38
Brandyn Moore, Raphael Prodromou, Gabrielle Rusch, et al.
ACS Applied Engineering Materials (2025)
Closed Access
FMS-Like Tyrosine Kinase 3 Inhibitors in the Treatment of Acute Myeloid Leukemia: An Update on the Emerging Evidence and Safety Profile
Sylvain Garciaz, Marie‐Anne Hospital
OncoTargets and Therapy (2023) Vol. Volume 16, pp. 31-45
Open Access | Times Cited: 10
Palmitoyltransferase ZDHHC6 promotes colon tumorigenesis by targeting PPARγ-driven lipid biosynthesis via regulating lipidome metabolic reprogramming
Junqi Shan, Xinyu Li, Runqi Sun, et al.
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 3
Combination Therapies with Kinase Inhibitors for Acute Myeloid Leukemia Treatment
Shinichiro Takahashi
Hematology Reports (2023) Vol. 15, Iss. 2, pp. 331-346
Open Access | Times Cited: 9
FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review
Amal Kamal Abdel‐Aziz, Eman M.E. Dokla, Mona Kamal Saadeldin
Critical Reviews in Oncology/Hematology (2023) Vol. 191, pp. 104139-104139
Open Access | Times Cited: 9
Enhancing Therapeutic Efficacy of FLT3 Inhibitors with Combination Therapy for Treatment of Acute Myeloid Leukemia
Malia E. Leifheit, Gunnar Johnson, Timothy M. Kuzel, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 17, pp. 9448-9448
Open Access | Times Cited: 2
AML under the Scope: Current Strategies and Treatment Involving FLT3 Inhibitors and Venetoclax-Based Regimens
Szymon Milnerowicz, Julia Maszewska, Paulina Skowera, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 21, pp. 15849-15849
Open Access | Times Cited: 7
Broadening the horizon: potential applications of CAR-T cells beyond current indications
Hendrik Karsten, Ludwig Matrisch, Sophia Cichutek, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors
Melisa Tecik, Aysun Adan
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 6, pp. 719-751
Open Access | Times Cited: 1
PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia
Yong June Choi, Jaewoo Park, Hyoyi Choi, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115066-115066
Open Access | Times Cited: 4
Application of Quantitative Structure-Activity Relationships in the Prediction of New Compounds with Anti-Leukemic Activity
Cristian Sandoval, Francisco Torrens, Karina Godoy, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12258-12258
Open Access | Times Cited: 2
Tomatidine, a Steroidal Alkaloid, Synergizes with Cisplatin to Inhibit Cell Viability and Induce Cell Death Selectively on FLT3-ITD+ Acute Myeloid Leukemia Cells
Havva Berre Ayvaz, Münevver Yenigül, Emel Başak Gencer Akçok
Cell Biochemistry and Biophysics (2024) Vol. 82, Iss. 3, pp. 2889-2900
Closed Access
Lipopolymer/siRNA complexes engineered for optimal molecular and functional response with chemotherapy in FLT3-mutated acute myeloid leukemia
Aysha Ansari, Cezary Kucharski, K Bahadur, et al.
Acta Biomaterialia (2024) Vol. 188, pp. 297-314
Open Access
Clinical perspectives on post‐induction maintenance therapy in patients with acute myeloid leukaemia in remission who are ineligible for allogeneic haematopoietic stem cell transplantation
Kendra Sweet, Thomas Cluzeau
British Journal of Haematology (2024)
Closed Access
Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges
Jan Rataj, Lukáš Górecki, Darina Muthná, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 182, pp. 117788-117788
Open Access
Advances in Targeted Drugs for Adult Acute Myeloid Leukemia
真娇 刘
Advances in Clinical Medicine (2023) Vol. 13, Iss. 03, pp. 3911-3918
Closed Access
Upgrading Melanoma Treatment: Promising Immunotherapies Combinations in the Preclinical Mouse Model
Israel Lara-Vega
Current Cancer Therapy Reviews (2023) Vol. 20, Iss. 5, pp. 489-509
Closed Access
Targeting AML Growth: Vitamins' Influence on FLT3, NPM1, and RUNX1 Interactions
Tunnisha Dasgupta, Rounak Chatterjee, Moumita Mondal, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top